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Abstract Mitochondrial cytopathies constitute a group of
rare diseases that are characterized by their frequent
multisystemic involvement, extreme variability of pheno-
type and complex genetics. In children, renal involvement
is frequent and probably underestimated. The most frequent
renal symptom is a tubular defect that, in most severe
forms, corresponds to a complete De Toni-Debré-Fanconi
syndrome. Incomplete proximal tubular defects and other
tubular diseases have also been reported. In rare cases,
patients present with chronic tubulo-interstitial nephritis or
cystic renal diseases. Finally, a group of patients develop
primarily a glomerular disease. These patients correspond
to sporadic case reports or can be classified into two major
defects, namely 3243 A>G tRNA
LEU mutations and coenzyme
Q10 biosynthesis defects. The latter group is particularly
important because it represents the only treatable renal
mitochondrial defect. In this Educational Review, the principal
characteristics of these diseases and the main diagnostic
approaches are summarized.
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Coenzyme Q10
Components of the mitochondrial respiratory chain
Mitochondria are intracellular organelles that play a cardinal
role in generating adenosine triphosphate (ATP) through
oxidative phosphorylation (OXPHOS) and in modulating
other cell functions, such as apoptosis, response to oxidative
stresses, heat production, and various anaplerotic reactions [1,
2]. In this review, we restrict the term mitochondrial
cytopathy to genetic defects that directly or indirectly impair
OXPHOS. Briefly, the respiratory chain is composed of five
protein complexes that have two major functions, namely, to
transfer protons and electrons [from reduced nicotinamide
adenine dinucleotide phosphate (NADPH) and reduced
flavin adenine dinucleotide (FADH2) to oxygen molecules]
across the inner mitochondrial membrane and to generate
ATP (Table 1). The first task is performed by complexes I–IV
and generates the electrochemical gradient that allows
complex V, or ATP synthase, to form ATP from adenosine
diphosphate (ADP) and inorganic phosphate (reviewed in
[1–4]).
Within the mitochondrial respiratory chain, ubiquinone,
or coenzyme Q10 (CoQ10), plays a crucial role in shuttling
electrons from complexes I and II to complex III (Fig. 1)
[5]. CoQ10 is a ubiquitous lipophilic vitamin-like substance
first isolated in 1957 from beef mitochondria, which has the
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DOI 10.1007/s00467-011-1926-6highest concentration in tissues, with elevated energy
turnover (heart, brain, liver, kidney). It is comprised of a
quinone group and of a polyisoprenoid tail of different
length in different species: 6 subunits in yeast (CoQ6),
9 subunits in mice (CoQ9), and 10 subunits in humans
(CoQ10) (Fig. 1). It is endogenously synthesized through a
multienzyme complex located at the inner mitochondrial
membrane [6], which is encoded by at least 16 genes. The
functions of CoQ10, however, are not restricted to bioener-
getics; CoQ10 is also an important cofactor of several
mitochondrial dehydrogenases, a modulator of the mito-
chondrial permeability transition pore that acts as a gating
channel for apoptosis, and an important antioxidant [7].
Approximately 0.2% of oxygen molecules are not reduced
into water during OXPHOS and form reactive oxygen
species (ROS) that can be converted into highly reactive
hydroxyl radicals (OH
￿) that cause oxidative damage to
DNA, lipids, and proteins [1, 2]. Accumulation of free
radicals probably plays a crucial role in the physiopathol-
ogy of many mitochondrial diseases [8]. In normal
conditions, ROS are scavenged by superoxide dismutase,
catalase, and glutathione peroxidase, but CoQ10 and other
molecules, such as vitamin C and vitamin E (α-tocopherol),
also play a crucial role as lipid-soluble antioxidants [1, 5].
Genetics
Each mitochondria has several copies of its own double-
stranded mitochondrial DNA (mtDNA) that forms a circular
string of 16,569 bp. mtDNA encodes 37 genes, including all
22 transfer RNAs (tRNAs) necessary for protein synthesis,
two ribosomal RNA (rRNA) subunits, and 13 structural
proteins of the mitochondrial respiratory chain (Table 1). The
majority of structural proteins that compose mitochondria
(>1,000) and the totality of functional proteins that are
necessary for mitochondria assembly and degradation are
encoded by nuclear genes [3, 9]. Spermatozoa do not
contribute to the zygote with mitochondria; mutations in
mtDNA are therefore inherited from the mother (i.e.,
maternal inheritance). mtDNA abnormalities were first
linked to human disease in 1988. In that year, Leber’s
Table 1 Respiratory chain complexes
Complex Name Subunits encoded
by mtDNA
Subunits encoded
by nuclear genes
Total subunits
Complex I NADH-ubiquinone oxidoreductase ND1, ND2, ND3, ND4, ND5, ND6, ND4L ~39 ~46
Complex II Succinate-ubiquinone oxidoreductase None 4 4
Complex III Ubiquinol-cytochrome c oxidoreductase Cytochrome-b 10 11
Complex IV Cytochrome c oxidase COX I, COX II, COX III 10 13
Complex V ATP synthase ATPase 6, ATPase 8 12 14
Total 13 ~75 ~88
mtDNA mitochondrial DNA, NADH nicotinamide adenine dinucleotide, reduced, ATP adenosine triphosphate, COX cytochrome c oxidase
Fig. 1 Coenzyme Q10 and the
electron flow in the respiratory
chain. The figure depicts the
central role of coenzyme Q10
(CoQ10) in shuttling electrons
from complexs I and II to com-
plex III. It is also an important
cofactor for several mitochondrial
dehydrogenases, such as dihy-
droorotate dehydrogenase
(DHODH). The insert shows the
structure of CoQ10, which is
comprised of a quinone group
and a polyisoprenoid tail of
different length, ranging from six
isoprenyl subunits in yeast to
ten subunits in humans.
Respiratory chain complexes
are detailed in Table 1
540 Pediatr Nephrol (2012) 27:539–550hereditary optic neuropathy and other progressive muscle
disorders were found to be caused by mutations in mtDNA
[10, 11]. Since the first descriptions, a large number of
disease-causing mutations in mtDNA have been reported and
are collected in the MITOMAP human mitochondrial
genome database (http://www.mitomap.org). Their preva-
lence in the general population is probably underestimated
and may be as high as 1–2:10,000 live births [12].
Mutations primarily include base substitutions or inser-
tions–deletions. Diseases resulting from missense mutations
are generally maternally transmitted. They can directly alter
mitochondrial proteins or impair protein synthesis if they
involve structural RNAs [tRNAs or rRNA]. Insertion–
deletion mutations can be spontaneous, maternally
inherited, or Mendelianly inherited due to predisposing
nuclear mutations. Spontaneous rearrangements of mtDNA
can also be responsible for various clinical syndromes and
reflect the gradual loss of autonomy throughout evolution
of the mitochondrial genome, which has become increas-
ingly dependent upon factors encoded by nuclear genes for
transcription, translation, and replication. These disorders
are due to mutations in nuclear genes that directly or
indirectly control mtDNA number, function, or integrity
[13]. Progressive mtDNA depletion diseases represent other
examples of the interplay between mitochondrial and
nuclear genomes and are secondary to defects in nuclear
genes that regulate mtDNA replication. Finally, somatic
mtDNA mutations are very frequent and may occur
preferentially in specific tissues, particularly in skeletal
muscles [13].
As opposed to nuclear genes, the genetic information
for proteins encoded by mtDNA is present in hundreds
of copies per cell. Mutations can affect all mtDNA
copies of an affected individual—a condition referred to
as homoplasmy—or may affect only a portion of the
entire mtDNA endowment of cells—termed hetero-
plasmy. In case of heteroplasmy, the impact of a given
mutation depends on the relative proportion of mutated
and wild-type mtDNA copies [8]. Cell dysfunction occurs
when the proportion of mutated mtDNA exceeds a given
threshold level, which is dependent on cell OXPHOS rates
[3]. Tissues with high metabolic rates, such as brain,
skeletal muscles, heart, and renal tubules, are particularly
exposed [3]. Symptoms may be delayed until late
childhood or adulthood, when the number of cells with a
high copy number of mutated mtDNA exceeds the
compensatory ability of neighboring cells. Examples of
this phenomenon include Leber’s optic atrophy, myoclonic
epilepsy with ragged red fibers (MERRF) syndrome or focal
segmental glomerulosclerosis (FSGS) related to tRNA
LEU
mutations. Conversely, a positive selection, favoring replica-
tion of healthier cells, can occur in tissues with high cell
turnover. Mutations may also be distributed unevenly
during early stages of embryogenesis, which causes
differences in penetrance of a given mutation in tissues
originating from different embryonic lineages. Finally, the
proportion of mutated mitochondria varies significantly from
one oocyte to the other, causing significant differences in
disease expression among siblings [13]. For all the above
reasons, diseases caused by mtDNA mutations are charac-
terized by the extreme heterogeneity of their clinical
symptoms.
A few years after the first reports of diseases caused by
mtDNA mutations, mitochondrial cytopathies caused by
defects in nuclear genes were reported [14]; these con-
ditions are inherited with a Mendelian trait in an autosomal
recessive or dominant mode. Surprisingly, a similar vari-
ability in the clinical picture as in mtDNA defects also
characterizes nuclear gene mutations. Such phenotypic
variability is related, at least in part, to the stochastic nature
of mitochondrial physiology, where a dynamic balance
exists between high rates of endogenous mtDNA mutations
and mtDNA repair mechanisms, including control of
mtDNA copy number [15], and between constitutive
mitochondrial damage and mitochondria turnover processes
(assembly and degradation). These mechanisms are also
thought to play a significant role during aging. From a
taxonomic perspective, several classifications of mitochon-
drial cytopathies have been proposed based on mutation
type, and/or biochemical defects, and/or clinical symptoms
[1, 3].
Clinical symptoms of mitochondrial cytopathies
Nearly all organs may be affected by mitochondrial
cytopathies. The clinical presentation is heterogeneous; it
may reflect involvement of single organs but commonly
symptoms are multisystemic. The most frequent symptoms
and features [16] are summarized in Table 2.
Skeletal muscles are frequently affected, in part because
somatic mutations occur more frequently in myoblasts or
myoblast precursors. Exercise intolerance is a common
complaint, which is often dismissed as psychogenic or
mislabeled as chronic fatigue syndrome or rheumatic
fibromyalgia, unless patients have objective muscle weak-
ness, increased serum creatine kinase levels, or abnormal
electromyography findings [13]. Many patients with
mtDNA mutations fall into this group; the frequent lack
of a clear maternal inheritance further deflects the physician
from considering a mitochondrial cytopathy [13]. If not
initially present, central nervous system (CNS) symptoms
develop at some stage of the disease in most patients. Some
symptoms, such as sensorineural deafness or myocardiop-
athy, may remain subclinical for many years and require
systematic screening. Endocrine (diabetes mellitus) and
Pediatr Nephrol (2012) 27:539–550 541ophthalmologic (ophtalmoplegia, ptosis, pigmentary retinal
degeneration) symptoms also frequently develop in the
course of the disease. Various skin and hair lesions have
also been described [17].
Overall,amajorcharacteristicofmitochondrialcytopathies
is the progressive nature of the multisystemic involvement,
withincreasingsymptomsdevelopingduringthecourseofthe
disease,asmoretissues becomeaffected. To date, >40 clinical
syndromes, based on the association of different symptoms,
have been reported [1, 3]. They are often designated by
acronyms, such as CPEO (chronic progressive external
ophthalmoplegia), MELAS (myopathy, encephalomyopathy,
lactic acidosis, and stroke-like episodes), MERRF, KSS
(Kearns-Sayre syndrome), LHON (Leber’sh e r e d i t a r yo p t i c
neuropathy), or NARP (neuropathy, ataxia, and retinitis
pigmentosa), for example. However, patients frequently have
distinctive characteristics, and many of these syndromes
overlap, which ultimately requires genetic testing for
accurate diagnosis [1].
Diagnosis of mitochondrial cytopathies
When suspecting a mitochondrial disorder, the first step is
generally to measure serum lactate levels, which are
frequently elevated, although often fluctuating. In oligo-
symptomatic diseases, such as in certain renal mitochon-
drial cytopathies, serum lactate may be normal. In addition
to blood, however, lactate can also be measured in other
body fluids, such as cerebrospinal fluid (CSF) and urine.
Brain lactate levels can be estimated by magnetic resonance
(MR) spectroscopy. If lactate levels are normal in all
sampled tissues, further genetic studies are not usually
recommended, unless other evidences of a mitochondrial
defect subsist. The diagnostic workup of renal mitochondrial
cytopathies requires a combination of different approaches,
including enzymology and biochemistry analyses, molecular
genetics, pathology (histology, histochemistry, electron mi-
croscopy), and neuroradiology studies, possibly coupled with
MR spectroscopy. Measurement of urine organic acids by gas
chromatography/mass spectrometry (GC-MS) is often useful.
Impaired respiratory chain activity causes accumulation
of reduced NADH, promoting conversion of acetoacetic
acid into 3OH-butyrate in the mitochondrion and the
conversion of pyruvate into lactate in the cytosol [18].
These compounds are easily detected in urines and, when
present in high amounts, are highly evocative of a mitochon-
drial dysfunction. Excess of other intermediate metabolites of
the Krebs cycle and other metabolic pathways are also
frequently observed. When the muscle biopsy is available,
the presence of ragged red fibers is a specific finding in
patients with mitochondrial diseases.
In tissues, the general rule is to perform tests on samples
collected from the most affected organs. However, in many
cases, this approach may be unreasonably aggressive, and
biochemical studies performed on cultured fibroblasts from
a skin biopsy are sufficient. Measuring respiratory-chain
complexes in the kidney, for example, requires a surgical
biopsy to obtain at least 3–4m m
3 of renal cortex. Similarly,
CoQ10 determination has been traditionally performed on
skeletal muscle [19], which is an invasive procedure in
infants, in whom obtaining sufficient amounts of tissue can
be problematic. Moreover, muscle biopsies need to be
performed before initiating CoQ10 supplementation. Fortu-
nately, CoQ10 can be reliably measured in cultured skin
fibroblasts [20], which also allow measuring the rate of
ubiquinone biosynthesis [21]. Fibroblasts can be easily
Table 2 Symptoms related to mitochondrial cytopathies
Affected system Manifestations
Neurological Apnea, hypotonia, lethargy, developmental
delay, psychomotor regression, ataxia,
stroke-like episodes, hemiparesis,
spasticity, seizures, dementia,
leukodystrophy, myoclonus, cortical
blindness, migraine, polyneuropathy
(sensory and/or motor), neurogenic
bladder
Muscular Myopathy, hypotonia, exercise intolerance
Hearing Hearing loss
Cardiac Cardiomyopathy, arrhythmias, heart block
Renal Proximal tubulopathy, De
Toni-Debré-Fanconi syndrome, proximal
tubular acidosis, Bartter-like tubulopathy,
hypermagnesuria, proteinuria, nephrotic
syndrome, tubulointerstitial nephritis,
myoglobinuria, renal failure
Endocrine Diabetes mellitus, hypoparathyroidism,
hypothyroidism, hyporeninemic
hypoaldosteronism, growth hormone
deficiency
Gastrointestinal Liver dysfunction, hepatomegaly, liver
failure, vomiting, diarrhea, malabsorption,
pseudoobstruction, intestinal dysmotility,
exogenous pancreatic insufficiency
Hematological Sideroblastic anemia, neutropenia,
thrombocytopenia
Ocular Progressive external ophtalmoplegia,
ophtalmoparesis, pigmentary retinal
degeneration, ptosis, cataract, optic
atrophy, blindness
Antenatal symptoms Dysmorphic features, malformations,
intrauterine growth retardation
polyhydramnios
Cutaneous Mottled pigmentation, discoloration,
acrocyanosis, vitiligo, cutis marmorata,
anhydrosis and jaundice, hyperhidrosis,
trichothiodystrophy, hirsutism alopecia,
alopecia with brittle hair, symmetric
cervical lipomas
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laboratories for diagnosis. Treatment can be started before
obtaining a skin biopsy, because oral CoQ10 supplementa-
tion does not influence test results in vitro. CoQ10
determinations can also be performed in blood mononucle-
ar cells [22]. However, no data on normal CoQ10 levels in
mononuclear cells of patients with primary CoQ10 defi-
ciencies are available; in addition, samples need to be
processed rapidly and cannot be shipped easily to labora-
tories that can measure CoQ10 concentrations.
Respiratory-chain activity can be assessed by various
methods (reviewed in [23]). Polarographic studies enable
integrated function of the mitochondrial respiratory chain to
be determined by measuring oxygen consumption in the
presence of oxidative substrates, such as pyruvate, gluta-
mate, malate, or succinate. Spectrophotometric studies
allow activities of the individual mitochondrial respiratory
chain complexes to be assayed. Complex II–III activity is
highly dependent upon endogenous CoQ10 [24]. Therefore,
decreased complex II–III activity in the presence of both
normal complex II and III activities may suggest a defect in
CoQ10 biosynthesis [25]. Results are influenced by the
number of tested mitochondria; typically, data are normal-
ized to the activity of citrate synthase. Both relative and
absolute values need to be analyzed to distinguish between
selective defects (low normalized values/normal citrate
synthetase activity) and severe mitochondria damage or
depletion (low or normal normalized values/low citrate
synthetase activity).
In tissue sections, the activity of mitochondrial
enzymes, such as cytochrome c oxidase (COX) and
succinate dehydrogenase (SDH), can be easily assessed
with histochemistry techniques [3, 26–28]. These assays
are routinely performed on muscle biopsy specimens but
can also be applied to other tissues, such as the renal
cortex. Contrary to biochemical measurements, these
studies only require frozen sections; they should be
performed preferably in parallel with sections obtained
from a normal kidney specimen mounted on the same
microscopy slide. Because COX is encoded in part by
mtDNA, and SDH is entirely encoded by nuclear genes,
these studies can demonstrate heteroplasmy by showing
cells with high SDH activity secondary to compensatory
mitochondrial proliferation and low COX activity [29]; in
other cases, they may show a more diffuse decrease in the
activity of both enzymes (Fig. 2). Electron microscopy,
when available, generally demonstrates abnormal mito-
chondria and mitochondrial proliferation or depletion.
Mitochondrial depletion is particularly apparent in prox-
imal tubular cells, which are rich in these organelles;
mitochondrial proliferation in podocytes of patients with
steroid-resistant nephrotic syndrome (SRNS) is evocative
of a CoQ10 defect.
Renal mitochondrial diseases
Kidney involvement is more frequently reported in children
than in adults [18]. Several renal diseases have been
reported over the past 2 decades, including tubular
disorders, chronic tubulointerstitial nephritis, cystic renal
disease, and glomerulopathies [18]. Glomerular diseases
comprise a small collection of sporadic cases and two major
clinical entities that, when kidneys are affected, primarily
present with glomerular involvement, namely, mtDNA
mutations in the gene encoding for the tRNA
LEU and
CoQ10 biosynthesis defects. In addition, myoglobinuria,
especially when recurrent, is commonly associated with
mitochondrial metabolic disorders that impair the use of
glycogen or fatty acids as sources of energy for muscle
contraction [30] and may cause tubular damage.
Tubular defects and other tubulointerstitial disorders
Proximaltubularcellshavehighmetabolicratesandarerichin
mitochondria. Notsurprisingly, themostfrequentrenaltubular
findingisaproximaltubulardefect,whichhasbeenreportedin
at least 60 patients; of these, 39 were summarized by Niaudet
and Rötig in 1997 [18]; 21 additional patients could be
identified in the literature [31–34], including a large Spanish
cohort reported by Martín-Hernández in 2005 [35]. In
approximately one third of patients, tubulopathy corre-
sponded to overt De Toni-Debré-Fanconi syndrome, usually
associated with low-molecular-weight proteinuria. In the
remaining patients, urinary losses were moderate and often
restricted to some substrates that are normally reabsorbed by
proximal tubular cells. In nearly all patients, extrarenal signs
were present, but cases in which tubulopathy was the only
sign of a mitochondrial disease have been reported [32, 33],
suggesting that lactaciduria should be checked in all patients
presenting with idiopathic De Toni-Debré-Fanconi syndrome
[35]. This tubulopathy is frequently associated with Pearson
and Kearns–Sayre syndromes [18, 35]. The most frequent
biochemical findings were complex III and/or complex IV
defects (nearly half of patients), followed by complex I
defects. From a genetic standpoint, all mutation types have
been reported, but the most frequent finding is the presence
of large mtDNA deletions. In the neonatal period or in the
first months of life, Fanconi syndrome is often observed in
patients with BCSL1 gene mutations associated with hepat-
opathy and complex III deficiency [36]. Several patients had
a pattern of symptoms consistent with known mitochon-
drial associations, including MERFF, Pearson’s, Kearns–
Sayre, and Leigh syndromes. Symptoms were present in
the neonatal period in one third of patients and in 80%
of cases by 2 years of age [18]. Renal biopsies, when
available, showed chronic tubulointerstitial changes, with
damaged proximal tubular epithelia; electron microscopy
Pediatr Nephrol (2012) 27:539–550 543often showed proliferation of abnormal mitochondria [18,
31].
Other tubular defects include a few cases reported as
renal tubular acidosis with hypercalciuria [37, 38] and
patients with a Bartter-like phenotype, which seems more
frequently associated with Kearns–Sayre syndrome [29,
39]. Finally, severe hypomagnesemia is often mentioned in
the descriptions of patients with mitochondrial tubulopa-
thies and has also been reported as an isolated finding
caused by excessive urinary magnesium losses [40]. Nine
Fig. 2 Detection of cytochrome c oxidase (COX) and succinate
dehydrogenase (SDH) activities in kidney cortex sections. Examples
of abnormal histochemical staining in the renal cortex of three patients
with a mitochondrial defect. a Uneven staining for COX and SDH in
different tubular sections; b very low COX activity with normal SDH
activity; c undetectable activity of both enzymes in tubular cells
544 Pediatr Nephrol (2012) 27:539–550patients presenting with chronic renal failure secondary to
tubulointerstitial nephritis, without evidence of a primary
tubular defect, have been reported [41–43]. Cystic renal
changes have also been rarely described in association with
mitochondrial cytopathies [44–46]. When approaching
patients with a mitochondrial tubulopathy, clinicians should
keep in mind that mitochondrial damage can also be
secondary to other causes, including metabolic diseases
(tyrosinemia type I, for example [47]), drugs (ifosfa-
mide, for example [48]), or toxic agents, in particular
heavy metals (cadmium, for example [49]). Recently, a De
Toni-Debré-Fanconi syndrome secondary to antimito-
chondrial antibodies in two patients with primary biliary
cirrhosis was described [50]. Finally, renal symptoms of
mitochondrial tubulopathies are frequently sub-clinical or
can be overshadowed by extra-renal symptoms. Among
the 42 children with established mitochondrial disorders
studied by Martín-Hernández et al for example, 50% had a
renal tubular dysfunction, but only eight had overt
disease, indicating that both tubular and glomerular
functions should always be monitored in patients with
mitochondrial disorders [35].
Sporadic cases of glomerular involvement
Sclerotic glomerular lesions are often described in renal
mitochondrial diseases and are thought to be secondary to
tubular and tubulointerstitial lesions. Few sporadic cases
presenting with primary glomerular lesions have been
reported. Güçer et al. described two patients with different
mtDNA deletions [51]. The first patient was a 9-year-old
girl with a common 4.9-kb mtDNA deletion, who presented
with hematuria and proteinuria associated with ptosis and
ophthalmoplegia, failure to thrive, high serum lactate and
pyruvate levels, and ragged red fibers on muscle biopsy.
Her renal function remained stable on angiotensin-
converting enzyme (ACE) inhibitors after 5 years. The
second patient presented with nephrotic syndrome (NS) at
4 months of age associated with poor feeding, vomiting,
seizures, and nystagmus. Her laboratory investigations
demonstrated high serum and CSF lactate levels and
massive cerebral atrophy with white matter degeneration.
On renal biopsy, podocytes showed proliferation of pleo-
morphic mitochondria. She rapidly died and was found to
have a heteroplasmic mtDNA deletion [52]. Goldenberg et
al. reported three patients presenting with congenital NS
[53]: Two siblings presented with NS and heart failure and
died within the first week of life; they both had low
complex [II+III] activity, raising the hypothesis of a CoQ10
biosynthesis defect. The third patient had intrauterine
growth retardation and presented with NS at birth without
lactacidemia but with increased lactaciduria. In his second
year of life, the patient developed end-stage renal disease
(ESRD), seizures, and carnitine-responsive cardiac failure.
Hameed et al. described a 6-year-old boy who presented
with SRNS associated with hypoparathyroidism and senso-
rineural deafness [44]. The child progressed to ESRF and
was successfully transplanted. He later developed an
encephalomyopathy. MR studies were consistent with a
previous encephalopathy or with leukodystrophy; muscle
biopsy showed ragged red fibers. Three other cases were
summarized by Niaudet et al. [18].
Renal disease in tRNA
LEU gene mutations
To date, the most prevalent mtDNA defect is the 3243 A >
G point mutation in the leucine tRNA gene, which was
initially described in children with MELAS syndrome [2,
3]. The clinical manifestations of the 3243 A > G mutation,
however, are not restricted to full-blown MELAS syndrome
but can also express as diabetes, deafness, gastrointestinal
and/or neuromuscular symptoms [2, 54]. This mutation is
observed in nearly 1% of the diabetic population [55]. In
1997 Jansen et al. reported on their screening for the 3243
A > G mutation in diabetic patients with a history of
maternally inherited diabetes and/or sensorineural hearing
loss and described four women who had undergone renal
transplantation for a proteinuric renal disease. Since then, at
least 27 cases (+ several of their relatives) have been
described, which were identified by screening patients with
renal diseases and a personal or familial (maternal) history
of diabetes or deafness [54–62]. When sensorineural
deafness is present, patients can also be misleadingly
diagnosed with Alport syndrome; a total of 90 Alport
patients have been systematically screened in two studies
for a MELAS mutation, allowing identification of two
misdiagnosed cases [55, 59]. The majority of patients in
these reports were females (20/27). When studied, diabetes
and/or deafness was very frequently present in the pro-
band’s mother and other family members [55, 57–59]. Age
at mtDNA mutation diagnosis ranged from 14 to 50 years.
The prevalent renal histology findings (22/27) were
consistent with FSGS. Four cases of chronic tubulointer-
stitial nephritis and one case presenting with cystic kidney
disease have also been described [54, 62]. A peculiar
vasculopathy with hyalinosis of small arteries and myocyte
necrosis was noted in two reports [56, 57]. By electron
microscopy, pleomorphic mitochondrial accumulation has
been occasionally documented in podocytes [58]o ri n
tubular cells [62] but is usually absent. All patients had
high urinary protein excretion; NS developed in approxi-
mately one third of cases. Proteinuria generally began in the
second or third decade of life, with the youngest patient
diagnosed at age 5 [54]. Most patients were hypertensive;
two female patients developed preeclampsia [56]. Chronic
or end-stage renal failure developed within 10 years in
Pediatr Nephrol (2012) 27:539–550 545approximately 50% of cases. A majority of patients had
extrarenal symptoms at diagnosis; some–in particular, younger
patients–developedthesesymptomsduringfollow-up[54–62].
Deafness was present in 22/27 cases; nearly half required
hearing aids after the age of 30. Diabetes mellitus was
reported in 15/27 patients. Other reported findings include
neuromuscular symptoms (five patients), retinal dystrophy
(two patients), and cardiomyopathy (two patients). Serum
lactate and pyruvate were generally normal.
CoQ10 biosynthesis defects
Primary CoQ10 deficiency deserves a special mention among
mitochondrial renal defects because it is the only treatable
mitochondrial disorder. It was first reported in 1989 in
association with myopathy and encephalopathy [19]a n d
later with cerebellar ataxia [63]. The link between CoQ10 and
renal disease was established in 2000 when three siblings
were diagnosed with a complex clinical syndrome charac-
terized by progressive encephalopathy and SRNS [64]. Two
siblings developed ESRF and required transplantation at age
8 and 9, respectively; the third sibling had a more severe
course and died at 8 years of age after rapid neurological
deterioration. The two surviving children were treated with
oral CoQ10 (5 mg/kg daily), which resulted in a substantial
improvement of their neurologic condition over 3 years,
demonstrating that primary CoQ10 deficiencies may respond
to oral CoQ10 supplementation. Two other siblings with
similar clinical features were reported in 2005 [65]. Both
developed SRNS at 12 months of age. The first child
developed progressive encephalomyopathy and stroke-like
episodes at 18 months. Oral CoQ10 therapy was initiated at
22 months of age and was able to stop encephalomyopathy
progression. The younger sister was treated immediately
after she developed proteinuria and had an excellent clinical
response without developing neurologic symptoms [66].
Mutations in the COQ2 gene were identified in these two
siblings as the first report of a genetic defect associated with
primary CoQ10 deficiency [67]. COQ2 encodes for para-
hydroxybenzoate polyprenyl transferase, the enzyme that
joins the polyprenoid tail to the quinone group of CoQ10 [68]
(Fig. 1). COQ2 mutations have been found in four additional
patients, all presenting with congenital or early-onset SRNS
[25, 69]. Mutations in two other genes involved in CoQ10
biosynthesis have been identified in patients with similar
clinical features, namely, in the COQ1-PDSS2 gene (one
patient) [70] and in the COQ6 gene (11 patients from five
different kindreds) [71]. Although disease characteristics and
progression are variable, all patients developed a glomerul-
opathy. Symptoms always began within the first years of life;
SRNS was the presenting symptom in most cases and
remained the only clinical manifestation in milder forms.
Unless treated, renal disease rapidly progressed to ESRF.
Associated clinical features include deafness and encephalo-
myopathy in COQ6 patients; severe forms with neonatal
onset may also present with liver failure and severe lactic
acidosis [25, 69]. Defects in genes required for CoQ10
biosynthesis can also present with other phenotypes. The
only reported patient with COQ9 mutations, for example, had
severe multisystem disorder with a renal tubulopathy but no
apparent glomerular involvement [72]; patients with mutations
in the COQ8-ADCK3,o rCOQ1-PDSS1 genes, on the other
hand, do not develop renal disease (Table 3)[ 69, 73, 74]. The
reasons underlying these discrepancies remain unclear; the
number of reported patients is too small to draw final
conclusions and to analyze genotype–phenotype correlations.
The histological picture in CoQ10-related diseases with
glomerular involvement varies, from FSGS to collapsing
glomerulopathy [25, 75]; electron microscopy generally
shows numerous dysmorphic mitochondria in the cytoplasm
of podocytes [25, 75]. One of the most important aspects of
CoQ10 biosynthesis defects is the clinical response to oral
supplementations. Despite improvement in neurological
symptoms after high oral doses of CoQ10, the initial reports
did not show the same benefits on renal lesions, because
patients already had advanced kidney disease [64, 65].
Conversely, when treatment was initiated in one girl
immediately after onset of renal symptoms, prompt reduction
of proteinuria was observed; the patient had normal renal
function nearly 5 years after starting treatment [66]. A
Gene Number of
patients
Renal
phenotype
Other features Response
to therapy
COQ1-PDSS1 2 No Multisystem disorder ±
COQ1-PDSS2 1 SRNS Progressive encephalomyopathy +++
COQ2 6 SRNS Progressive encephalomyopathy
with liver failure
+++
COQ6 10 SRNS Deafness seizures +++
COQ7 - ? (Mouse knock-out is lethal) ?
COQ8-ADCK3 >10 No Cerebellar ataxia ±
COQ9 1 Tubulopathy Lactic acidosis, encephalomyopathy ±
Table 3 Characteristics of
known coenzyme Q10 (CoQ10)
biosynthesis gene defects
546 Pediatr Nephrol (2012) 27:539–550similar response has also been documented in two patients
with COQ6 mutations [71].
However,severalissuesremainopen.Thebioavailabilityof
CoQ10, for example, is poor; moreover, transfer of exogenous
CoQ10 to mitochondria is a slow process that requires almost
1 week in cultured cells [76]. The relationship between
CoQ10 plasma and tissue levels is poor [77]. Empirically,
CoQ10 doses of 30–50 mg/kg per day have been given to
patients [66, 71], but there is no practical method to monitor
the efficacy of therapy other than observing the clinical
response. In theory, higher dosages could be advantageous,
especially in the first phase of treatment, in order to restore
normal body CoQ10 content. Currently, a multicenter trial
testing the efficacy of 10 mg/kg per day of CoQ10 in children
with biochemically proven deficiencies of complex I, III, or
IV or with mutations in respiratory-chain genes is underway
(NCT00432744). Different pharmaceutical formulations of
CoQ10 are commercially available; although it is probably
preferable to prescribe oral suspensions rather than tablet
preparations that contain crystalline forms of CoQ10 [78], no
systematic pharmacokinetic studies have been performed in
CoQ10-deficient patients. Hopefully, studies on animal mod-
els, such as the kd mouse that harbors a homozygous
mutation in the PDSS2 gene [79], will also help optimize
treatment. Regardless of the results of these studies, evidence
indicates the absolute necessity of initiating treatment early to
prevent the development of irreversible lesions, especially in
the brain and kidneys [66]. Therefore, a suspicion of a
mitochondrial dysfunction secondary to CoQ10 deficiency
should always arise in patients with early-onset SRNS,
especially when podocyte mitochondrial abnormalities are
observed by electron microscopy, in the presence of lactaci-
duria or when neurologic or muscular symptoms are present.
The diagnosis of CoQ10 deficiency is only available in
specialized centers and can be performed on cultured skin
fibroblasts. Meanwhile, treatment can be started in highly
evocative patients. No data are available on prenatal diagnosis,
which would allow treatment immediately after birth and,
potentially, maternal supplementation during pregnancy.
Questions:
1. Which ofthese statementsiscorrectinrespecttomtDNA:
A. As opposed to nuclear DNA, mtDNA is single
stranded
B. Containsthe nuclear informationofall mitochondrial
proteins
C. Mutations are always evenly distributed in cells
D. It forms a circular string that varies in length
among individuals
E. None of the above is correct
2. Which of the following organic acids is highly
evocative of a renal mitochondrial cytopathy when
found in excess in urine:
A. 3 OH-butyrate
B. Succinate
C. Fumarate
D. Phenyl acetone
E. None of the above
3. The most frequent renal disease in mitochondrial
cytopathies is:
A. Renal vascular disease
B. Chronic interstitial nephritis
C. Proximal tubulopathy
D. Glomerulopathy
E. None of the above
4. Which of the following statements is correct:
A. Clinical or subclinical renal involvement is always
present in mitochondrial cytopathies
B. All patients with mitochondrial cytopathies have
neuromuscular symptoms
C. Patients generally become symptomatic after the
age of 5 years
D. FSGS lesions in patients with a maternal history of
diabetes and deafness is evocative of a mutation of
the tyrosine tRNA gene
E. None of the above
5. Which of the following statements is correct:
A. Mitochondrial coenzyme Q10 derives primarily
from de novo synthesis
B. Coenzyme Q10 is present in the normal diet
C. Mutations in genes involved in the biosynthesis of
coenzyme Q10 may cause NS
D. Symptoms related to coenzyme Q10 defects may be
prevented by oral ubiquinone supplements
E. All of the above
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